 The primary objective of this study is to evaluate the safety and performance of coronary artery stenting with the NIRxTM Paclitaxel-Coated Stent 1.0μgmm2 of paclitaxel incorporated into slow- and moderate-release formulation of a triblock copolymer carrier system for the treatment of de novo lesions in native vessels. Patients in 2 sequential cohorts will be randomised to receive either the NIRxTM Paclitaxel-Coated Stent or the uncoated control stent. In cohort 1, the slow-release formulation NIRxTM Paclitaxel-Coated Stent will be studied. If the safety profile is acceptable, the moderate-release formulation NIRxTM Paclitaxel-Coated Stent will be studied in Cohort 2. In each f the 2 cohorts, 133 patients will be treated with the NIRxTM paclitaxel-Coated Stent and 133 with the uncoated control stent 1.1 ratio, for a total of 532 patients in study. 